Key result
New oral factor Xa inhibitors such as rivaroxaban and apixaban offer advantages over previous compounds but require attention during translation from clinical trials into daily practice.
Population
Patients requiring anticoagulation for prevention or treatment of venous thromboembolism, atrial…
Design
Review
Authors
Loading...
Warrants vigilance when adopting factor Xa inhibitors in practice; leaves open their performance across unselected real-world populations.
Direct oral factor Xa inhibitors offer a convenient route of administration with predictable pharmacokinetics that allow fixed dosing without coagulation monitoring, though translation to daily clinical practice requires careful attention.
Romualdi et al. (2011) conducted a review in Thrombosis and acute coronary syndromes. Factor Xa inhibitors (rivaroxaban and apixaban) was evaluated. New oral factor Xa inhibitors such as rivaroxaban and apixaban offer advantages over previous compounds but require attention during translation from clinical trials into daily practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: